SNPX קפיטליזציה חשבונאית Synaptogenix

Bankruptcy risks dominate Synaptogenix, Inc. (SNPX) due to the depletion of funds following failed Alzheimer's drug trials, necessitating a revision of the R&D strategy. While demand for dementia treatment remains stable, the share price is influenced by the availability of capital for new offerings, which currently stands at 0.00. This daily price chart on GURU.Markets complements the picture of managing a micro-cap biotech where a team with a scientific background is focused on a single asset.

Book value capitalization measures the value of net assets minus liabilities, capturing the company's actual capital cushion. The current value of 0.00 on the book value of net assets chart reflects a rapid depletion of resources at Synaptogenix, Inc. (SNPX) due to a lack of revenue and high pre-commercial research costs, signaling a critical level of operational cash burn.